NCNA - NuCana plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.10
+0.21 (+0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.89
Open23.45
Bid21.16 x 100
Ask26.95 x 700
Day's Range22.56 - 23.80
52 Week Range9.32 - 32.00
Volume46,576
Avg. Volume35,239
Market Cap723.286M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2,333.95
Trade prices are not sourced from all markets
  • Better Know Biotech: 2 Stocks You've Got to Know About
    Motley Fool2 months ago

    Better Know Biotech: 2 Stocks You've Got to Know About

    These two small-cap biotech stocks could be about to make it big.

  • GlobeNewswire2 months ago

    NuCana to Participate in the Jefferies 2018 Global Healthcare Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2018 Global Healthcare Conference in New York on Thursday, June 7, 2018 at 11:30 AM EDT. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire2 months ago

    NuCana Reports First Quarter 2018 Financial Results

    EDINBURGH, United Kingdom, May  23, 2018  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, ...

  • GlobeNewswire2 months ago

    NuCana Reports First Quarter 2018 Financial Results

    EDINBURGH, United Kingdom, May 23, 2018-- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced financial results for ...

  • GlobeNewswire2 months ago

    NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced the appointment of Dr. Cyrille Leperlier to its Board as an independent non-executive Director.  NuCana`s ProTide(TM) technology transforms some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Dr. Leperlier brings to NuCana over 30 years of experience in the pharmaceutical and biotechnology industry.  Most recently, Dr. Leperlier served as Senior Scientific Advisor for Sanofi`s Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi`s acquisition of Genzyme.  Prior to this role, Dr. Leperlier served as Medical Director in Japan for Sanofi.  Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles.  Dr. Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris.

  • GlobeNewswire2 months ago

    NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced the appointment of Dr. Cyrille Leperlier to its Board as an independent non-executive Director.  NuCana’s ProTide™ technology transforms some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Dr. Leperlier brings to NuCana over 30 years of experience in the pharmaceutical and biotechnology industry.  Most recently, Dr. Leperlier served as Senior Scientific Advisor for Sanofi’s Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi’s acquisition of Genzyme.  Prior to this role, Dr. Leperlier served as Medical Director in Japan for Sanofi.  Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles.  Dr. Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris.

  • GlobeNewswire2 months ago

    NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland

    NuCana plc (NCNA) announced today it has been honored with two prestigious awards from Life Sciences Scotland during its annual Life Sciences Awards gala event held in Glasgow on May 16, 2018. Hugh S. Griffith, Chief Executive Officer and Founder, was presented with the Outstanding Contribution award. NuCana is a rapidly growing clinical-stage biopharmaceutical company applying an innovative new technology to significantly improve treatment for cancer patients.

  • GlobeNewswire3 months ago

    NuCana plc Announces Appointment of Adam George to its Board of Directors

    EDINBURGH, United Kingdom, April 09, 2018 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...

  • GlobeNewswire4 months ago

    NuCana Reports Financial Results for the Year Ended December 31, 2017

    EDINBURGH, United Kingdom, March 21, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the year ended December 31, 2017 and provided an update on its extensive clinical ...

  • GlobeNewswire5 months ago

    NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference

    EDINBURGH, United Kingdom, March 02, 2018 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...

  • ACCESSWIRE6 months ago

    Wired News – NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018

    LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on NuCana PLC (NASDAQ: NCNA ). If you want access to this report all you need to do is sign up ...

  • Market Exclusive6 months ago

    Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF)

    NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMOTH:PHMMF) are two big biotech movers heading into the start of a fresh week in the space, with both companies attracting volume based on the release of fresh data. Here is a look at the data from each and what it means for developing programs of the companies going […] The post Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF) appeared first on Market Exclusive.

  • GlobeNewswire6 months ago

    NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer

    NuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract Cancer EDINBURGH, United Kingdom, January 19, 2018 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced interim ...

  • GlobeNewswire8 months ago

    NuCana plc to Participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

    EDINBURGH, United Kingdom, Nov. 20, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...

  • GlobeNewswire8 months ago

    NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

    PRO-105 Study Will Evaluate up to 64 Patients EDINBURGH, United Kingdom, Nov.  15, 2017  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced the enrollment of the first patients in both the United States ...

  • Benzinga9 months ago

    Analysts See Potential In The NuCana Pipeline

    Jefferies and Citigroup initiated coverage for NuCana PLC (ADR) (NASDAQ: NCNA ) Monday with a Buy rating and a price target of $25 and $23 respectively. Jefferies' analysts Eun Yang and Carmen Augustine ...

  • GlobeNewswire10 months ago

    NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs

    EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...